Publications by authors named "Edwin de Wit"

Claim this Profile
T
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Laurie H Sehn, Kai Hübel, Stefano Luminari, Christian W Scholz, Antonio Salar, Edwin de Wit

Lancet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Michele Cavo, Evangelos Terpos, Joan Bargay, Hermann Einsele, Jim Cavet, Edwin de Wit

Expert Rev Hematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Philippe Moreau, Edwin de Wit

Br J Haematol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Agents in Multiple Myeloma: An Examination of Safety Profiles.
Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos

Clin Lymphoma Myeloma Leuk· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Pieter Sonneveld, Edwin De Wit, Philippe Moreau

Crit Rev Oncol Hematol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
David J Vaughn, Sandy Srinivas, Walter M Stadler, Roberto Pili, Daniel Petrylak, Edwin de Wit

Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis